370 related articles for article (PubMed ID: 33562306)
1. Emerging Roles for Ion Channels in Ovarian Cancer: Pathomechanisms and Pharmacological Treatment.
Altamura C; Greco MR; Carratù MR; Cardone RA; Desaphy JF
Cancers (Basel); 2021 Feb; 13(4):. PubMed ID: 33562306
[TBL] [Abstract][Full Text] [Related]
2. Ovarian cancer: Ion channel and aquaporin expression as novel targets of clinical potential.
Frede J; Fraser SP; Oskay-Özcelik G; Hong Y; Ioana Braicu E; Sehouli J; Gabra H; Djamgoz MB
Eur J Cancer; 2013 Jul; 49(10):2331-44. PubMed ID: 23683551
[TBL] [Abstract][Full Text] [Related]
3. Calcium signals and potential therapy targets in ovarian cancer (Review).
Deng F; Fu M; Zhao C; Lei J; Xu T; Ji B; Ding H; Zhang Y; Chen J; Qiu J; Gao Q
Int J Oncol; 2023 Nov; 63(5):. PubMed ID: 37711071
[TBL] [Abstract][Full Text] [Related]
4. Ion channels or aquaporins as novel molecular targets in gastric cancer.
Xia J; Wang H; Li S; Wu Q; Sun L; Huang H; Zeng M
Mol Cancer; 2017 Mar; 16(1):54. PubMed ID: 28264681
[TBL] [Abstract][Full Text] [Related]
5. HIF-2α-dependent TGFBI promotes ovarian cancer chemoresistance by activating PI3K/Akt pathway to inhibit apoptosis and facilitate DNA repair process.
Ma S; Wang J; Cui Z; Yang X; Cui X; Li X; Zhao L
Sci Rep; 2024 Feb; 14(1):3870. PubMed ID: 38365849
[TBL] [Abstract][Full Text] [Related]
6. Ovarian cancer ascites confers platinum chemoresistance to ovarian cancer cells.
Carmi YK; Agbarya A; Khamaisi H; Farah R; Shechtman Y; Korobochka R; Gopas J; Mahajna J
Transl Oncol; 2024 Jun; 44():101939. PubMed ID: 38489872
[TBL] [Abstract][Full Text] [Related]
7. Role of ion channels in gastrointestinal cancer.
Anderson KJ; Cormier RT; Scott PM
World J Gastroenterol; 2019 Oct; 25(38):5732-5772. PubMed ID: 31636470
[TBL] [Abstract][Full Text] [Related]
8. Odd-skipped related 1 plays a tumor suppressor role in ovarian cancer via promoting follistatin-like protein 1 transcription.
Yu Z; Ouyang L
Hum Cell; 2022 Nov; 35(6):1824-1837. PubMed ID: 35964260
[TBL] [Abstract][Full Text] [Related]
9. Downregulated expression levels of USP46 promote the resistance of ovarian cancer to cisplatin and are regulated by PUM2.
Xu L; Zhang B; Li W
Mol Med Rep; 2021 Apr; 23(4):. PubMed ID: 33576437
[TBL] [Abstract][Full Text] [Related]
10. Long non-coding RNA CTSLP8 mediates ovarian cancer progression and chemotherapy resistance by modulating cellular glycolysis and regulating c-Myc expression through PKM2.
Li X; Zhang Y; Wang X; Lin F; Cheng X; Wang Z; Wang X
Cell Biol Toxicol; 2022 Dec; 38(6):1027-1045. PubMed ID: 34510316
[TBL] [Abstract][Full Text] [Related]
11. TRAP1 downregulation in human ovarian cancer enhances invasion and epithelial-mesenchymal transition.
Amoroso MR; Matassa DS; Agliarulo I; Avolio R; Lu H; Sisinni L; Lettini G; Gabra H; Landriscina M; Esposito F
Cell Death Dis; 2016 Dec; 7(12):e2522. PubMed ID: 27977010
[TBL] [Abstract][Full Text] [Related]
12. Exosomal miRNA confers chemo resistance via targeting Cav1/p-gp/M2-type macrophage axis in ovarian cancer.
Kanlikilicer P; Bayraktar R; Denizli M; Rashed MH; Ivan C; Aslan B; Mitra R; Karagoz K; Bayraktar E; Zhang X; Rodriguez-Aguayo C; El-Arabey AA; Kahraman N; Baydogan S; Ozkayar O; Gatza ML; Ozpolat B; Calin GA; Sood AK; Lopez-Berestein G
EBioMedicine; 2018 Dec; 38():100-112. PubMed ID: 30487062
[TBL] [Abstract][Full Text] [Related]
13. The anti-tumor effect of OP-B on ovarian cancer in vitro and in vivo, and its mechanism: An investigation using network pharmacology-based analysis.
Yuan S; Xu Y; Yi T; Wang H
J Ethnopharmacol; 2022 Jan; 283():114706. PubMed ID: 34614446
[TBL] [Abstract][Full Text] [Related]
14. Silencing of miR-1246 Induces Cell Cycle Arrest and Apoptosis in Cisplatin-Resistant Ovarian Cancer Cells by Promoting ZNF23 Transcription.
Cai L; Zhang Q; Du L; Zheng F
Cytogenet Genome Res; 2021; 161(10-11):488-500. PubMed ID: 34923485
[TBL] [Abstract][Full Text] [Related]
15. CDCA3 exhibits a role in promoting the progression of ovarian cancer.
Gong S; Bai B; Sun G; Jin H; Zhang Z
Tissue Cell; 2022 Dec; 79():101903. PubMed ID: 36081320
[TBL] [Abstract][Full Text] [Related]
16. NUF2 promotes tumorigenesis by interacting with HNRNPA2B1 via PI3K/AKT/mTOR pathway in ovarian cancer.
Ren M; Zhao H; Gao Y; Chen Q; Zhao X; Yue W
J Ovarian Res; 2023 Jan; 16(1):17. PubMed ID: 36670423
[TBL] [Abstract][Full Text] [Related]
17. DMBT1 suppresses cell proliferation, migration and invasion in ovarian cancer and enhances sensitivity to cisplatin through galectin-3/PI3k/Akt pathway.
Ma N; Zhao Y
Cell Biochem Funct; 2020 Aug; 38(6):801-809. PubMed ID: 32424818
[TBL] [Abstract][Full Text] [Related]
18. Voltage-gated K+ channels are associated with cell proliferation and cell cycle of ovarian cancer cell.
Zhanping W; Xiaoyu P; Na C; Shenglan W; Bo W
Gynecol Oncol; 2007 Feb; 104(2):455-60. PubMed ID: 17014896
[TBL] [Abstract][Full Text] [Related]
19. Long non-coding RNA GAS5 inhibits DDP-resistance and tumor progression of epithelial ovarian cancer via GAS5-E2F4-PARP1-MAPK axis.
Long X; Song K; Hu H; Tian Q; Wang W; Dong Q; Yin X; Di W
J Exp Clin Cancer Res; 2019 Aug; 38(1):345. PubMed ID: 31391118
[TBL] [Abstract][Full Text] [Related]
20. Upregulation of CALD1 predicted a poor prognosis for platinum-treated ovarian cancer and revealed it as a potential therapeutic resistance target.
Li W; Huang L; Qi N; Zhang Q; Qin Z
BMC Genomics; 2024 Feb; 25(1):183. PubMed ID: 38365611
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
